Facebook Twitter RSS Feed

You are here

Heart Failure

 - diabetes, pharmaceutical, needle

In diabetic patients with heart failure (HF), sitagliptin use was found to have lower mortality rates but more subsequent HF hospitalizations than other therapies. Researchers noted there was no increased risk of all-cause hospitalizations, however.

 - merger, acquisition, money, handshake

Thoratec, which makes implantable devices for patients with advanced heart failure, paid $35 million to acquire an Irish company that specializes in transapical surgical access systems.

 - doctor and patient

Women with QRS of 130 milliseconds or greater see better outcomes than men when using cardiac resynchronization therapy (CRT). A study published online June 23 in JAMA Internal Medicine found that while women receive CRT defibrillation (CRT-D) less often than men, women with left bundle branch block and a QRS of 130 to 149 milliseconds had a 76 percent reduction in mortality and other heart failure-related events.

 - hosital admission

Use of home visits and multidisciplinary clinics helped to reduce all-cause readmissions and death up to six months after an index hospitalization for patients with heart failure, while telephone-based interventions also showed some success, according to a review of transitional care trials. But none seemed to lower 30-day readmission rates.

 - ICD

Heart failure patients with left ventricular ejection fraction (LVEF) between 30 and 35 percent do better with an implantable cardioverter-defibrilators (ICD) than without, a study published June 4 in JAMA confirmed. The findings also support guideline recommendations for use of ICDs in patients with LVEF of less than 30.

 

More Stories

HeartWare: Monitor VAD batteries

Heartware International has issued back-to-back warnings about its ventricular assist device (VAD), with the most recent notice involving batteries in the HeartWare Ventricular Assist System.

FDA puts Class I recall on HeartWare device

The FDA issued a Class I recall for the HeartWare Ventricular Assist Device due to a manufacturing flaw.

Heart failure stands out for costly readmissions

Congestive heart failure topped the list for 30-day readmissions of Medicare beneficiaries in 2011 and ranked among the top 10 high-volume conditions for two other payer categories in an analysis released in April.

FDA gives thumbs up to mini ICDs

The FDA approved the latest generation of Boston Scientific’s implantable cardiac devices.

FDA OKs use of biventricular pacing for less severe HF

The FDA expanded the indication for biventricular pacing using two types of cardiac resynchronization therapy devices to treat patients with atrioventricular block and mild to moderate heart failure (HF).

Circ retracts paper by its editor-in-chief

The journal Circulation retracted a 2012 article in which its editor-in-chief is a senior author, citing compromised data.

FDA approves 3 pacemaker devices

The FDA approved three St. Jude Medical pacemaker devices, including its quadripolar cardiac resynchronization therapy pacemaker.

'Bendopnea' identified as a possible symptom of heart failure

Experiencing shortness of breath while bending forward, termed “bendopnea,” could be an indicator of heart failure, according to researchers at the University of Texas Southwestern Medical Center in Dallas in a study published in the Journal of the American College of Cardiology.

Review: Diabetes drug trials should add HF hospitalization as outcome

Trials of new glucose-lowering drugs should consider hospitalization for heart failure as an outcome, according to a Personal View article published online March 13 in The Lancet. The authors argued that heart failure has not received much attention as an outcome in clinical trials of these drugs, but results have associated them with an increased risk of heart failure.

ICD-CRT may lead to fewer hospitalizations than ICD alone

Patients with heart failure who receive therapy consisting of an implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) have fewer hospitalizations than heart failure patients with only an ICD. The findings, published online March 7 in Circulation, were based on data from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).

LVAD bleeding risk varies based on patient factors

An analysis of HeartMate II left ventricular assist devices (LVADs) published in the March 11 issue of the Journal of the American College of Cardiology found that preoperative risk factors for bleeding and thrombotic events vary depending on patient demographics, including age, sex, body mass index and the cause of heart failure.

Saxagliptin’s heart failure finding prompts FDA review

The FDA is reviewing trial data for the diabetes drug saxagliptin after a published study found an increased rate of hospitalization for heart failure with treatment.

Serelaxin hits roadblock in Europe

The Committee for Medicinal Products for Human Use (CHMP) recommended that serelaxin not be approved as a treatment to relieve symptoms in patients with acute heart failure. The European committee’s decision could influence an FDA panel that will review the drug’s application in February.

Despite decline in use, rates of digoxin toxicity still high

Although clinicians use digoxin less frequently as newer, safer agents start taking its place, toxicity has not decreased, which suggests the need for better management and monitoring of the drug, according to a study published online Dec. 3 in Circulation: Heart Failure.

 

Higher heart rates at discharge linked to readmissions, death

Heart failure patients who have higher heart rates at discharge may face a higher risk of dying or being readmitted within 30 days, according to a study published online Dec. 2 in Circulation: Heart Failure.

Increased thromboses noted in patients with HeartMate II LVAD

Patients treated with the HeartMate II left ventricular assist device (LVAD) may be at higher risk for device thrombosis, based on the findings of a study published online Nov. 27 in the New England Journal of Medicine. Researchers found an increase in the number of thromboses compared with the results of pre-approval clinical trials.

 

More continuity needed in heart failure management

There are numerous medication therapy strategies along the continuum of managing heart failure (HF), and the authors of a review article published online Oct. 10 in The American Journal of Pharmacy Benefits argued that these various medication therapies need to be coordinated in a way that allows for continuity of care through each stage of treatment.

Some practices fail to treat heart failure according to guidelines

Not all cardiologists treat patients with heart failure and reduced ejection fraction according to established guidelines, and these variations in care are largely due to practice-level factors, according to a study published online Oct. 15 in Circulation: Heart Failure.

AHA sums up heart-related data on childhood cancer survivors

Survivors of childhood cancer are living longer, but over time the cardiotoxicity of some chemotherapies and radiation therapy may be taking a toll on their hearts. The American Heart Association published a scientific statement online Sept. 30 in Circulation that reviewed the evidence of cardiotoxicity in childhood survivors and highlighted future directions.

Hospitals' nesiritide use declines at different rates

Fewer hospitals now use nesiritide for heart failure due to safety concerns highlighted in 2005, and a study published in the August issue of the Journal of the American College of Cardiology: Heart Failure found that hospitals changed the way they use the drug in three distinct patterns. They categorized facilities as “low users,” “fast de-adopters” and “slow de-adopters,” but there were no significant differences between the groups in terms of hospital characteristics.